Dr. Sonneveld on Incorporating Genomic Profiling Into Myeloma Management

Pieter Sonneveld, MD, PhD
Published: Wednesday, Oct 12, 2016



Pieter Sonneveld, MD, PhD, head of the Department of Hematology, Erasmus University Medical Center, discusses how the incorporation of genomic profiling will play into the overall management of patients with multiple myeloma.

Gene expression profiling should be introduced as a predictor in clinical trials to identify patients with high-risk disease, Sonnevald explains. This represents approximately 15% to 20% of patients with multiple myeloma.

If identified properly, these patients can be selected for different treatment modalities. This is becoming easier, he explains, with the various therapies now FDA approved in this setting.


Pieter Sonneveld, MD, PhD, head of the Department of Hematology, Erasmus University Medical Center, discusses how the incorporation of genomic profiling will play into the overall management of patients with multiple myeloma.

Gene expression profiling should be introduced as a predictor in clinical trials to identify patients with high-risk disease, Sonnevald explains. This represents approximately 15% to 20% of patients with multiple myeloma.

If identified properly, these patients can be selected for different treatment modalities. This is becoming easier, he explains, with the various therapies now FDA approved in this setting.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x